Profund Advisors LLC decreased its position in Neurocrine Biosciences, Inc. (NASDAQ:NBIX) by 5.4% during the 2nd quarter, according to the company in its most recent disclosure with the Securities & Exchange Commission. The fund owned 33,602 shares of the company’s stock after selling 1,919 shares during the period. Profund Advisors LLC’s holdings in Neurocrine Biosciences were worth $1,546,000 at the end of the most recent quarter.
A number of other institutional investors have also recently bought and sold shares of NBIX. ARS Investment Partners LLC bought a new position in Neurocrine Biosciences during the second quarter worth about $207,000. Stephens Inc. AR bought a new position in shares of Neurocrine Biosciences during the 2nd quarter valued at about $207,000. Capstone Asset Management Co. bought a new position in shares of Neurocrine Biosciences during the 1st quarter valued at about $214,000. Grandfield & Dodd LLC lifted its holdings in shares of Neurocrine Biosciences by 15.2% during the 2nd quarter. Grandfield & Dodd LLC now owns 6,130 shares of the company’s stock valued at $282,000 after purchasing an additional 810 shares in the last quarter. Finally, Teacher Retirement System of Texas lifted its holdings in shares of Neurocrine Biosciences by 0.8% during the 2nd quarter. Teacher Retirement System of Texas now owns 6,966 shares of the company’s stock valued at $320,000 after purchasing an additional 57 shares in the last quarter.
Several equities analysts have recently weighed in on NBIX shares. ValuEngine upgraded Neurocrine Biosciences from a “strong sell” rating to a “sell” rating in a report on Friday, June 2nd. Jefferies Group LLC reissued a “buy” rating and issued a $67.00 target price on shares of Neurocrine Biosciences in a research report on Monday, May 22nd. BidaskClub raised Neurocrine Biosciences from a “sell” rating to a “hold” rating in a research report on Wednesday, June 21st. BMO Capital Markets lifted their target price on Neurocrine Biosciences from $75.00 to $84.00 and gave the company an “outperform” rating in a research report on Friday, August 4th. Finally, Piper Jaffray Companies set a $68.00 target price on Neurocrine Biosciences and gave the company a “buy” rating in a research report on Thursday, August 24th. Two research analysts have rated the stock with a hold rating and seventeen have assigned a buy rating to the company. The stock has a consensus rating of “Buy” and a consensus price target of $68.25.
Neurocrine Biosciences, Inc. (NBIX) opened at 56.56 on Tuesday. Neurocrine Biosciences, Inc. has a 52 week low of $37.35 and a 52 week high of $60.00. The stock’s 50 day moving average price is $54.15 and its 200 day moving average price is $49.08. The company’s market capitalization is $4.99 billion.
Neurocrine Biosciences (NASDAQ:NBIX) last released its earnings results on Thursday, August 3rd. The company reported ($0.68) earnings per share (EPS) for the quarter, missing the Zacks’ consensus estimate of ($0.67) by ($0.01). The business had revenue of $6.34 million during the quarter, compared to analyst estimates of $0.61 million. During the same period in the prior year, the company earned ($0.46) earnings per share. Analysts anticipate that Neurocrine Biosciences, Inc. will post ($2.45) earnings per share for the current year.
In other news, insider Christopher Flint Obrien sold 52,817 shares of the firm’s stock in a transaction on Tuesday, September 5th. The stock was sold at an average price of $57.50, for a total value of $3,036,977.50. Following the completion of the transaction, the insider now directly owns 101,790 shares of the company’s stock, valued at $5,852,925. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available through this hyperlink. Also, insider Haig P. Bozigian sold 26,250 shares of the firm’s stock in a transaction on Wednesday, September 6th. The stock was sold at an average price of $60.00, for a total value of $1,575,000.00. Following the completion of the transaction, the insider now directly owns 144,601 shares of the company’s stock, valued at $8,676,060. The disclosure for this sale can be found here. Insiders sold 125,655 shares of company stock valued at $7,018,148 over the last three months. Company insiders own 4.80% of the company’s stock.
ILLEGAL ACTIVITY WARNING: “Profund Advisors LLC Sells 1,919 Shares of Neurocrine Biosciences, Inc. (NBIX)” was originally published by Chaffey Breeze and is the property of of Chaffey Breeze. If you are reading this piece on another site, it was copied illegally and republished in violation of U.S. and international copyright laws. The correct version of this piece can be read at https://www.chaffeybreeze.com/2017/09/19/profund-advisors-llc-sells-1919-shares-of-neurocrine-biosciences-inc-nbix.html.
Neurocrine Biosciences Company Profile
Neurocrine Biosciences, Inc is engaged in discovering and developing pharmaceuticals, in diseases with unmet medical needs, through its research and development (R&D) platform, focused on neurological and endocrine based diseases and disorders. Its three lead late-stage clinical programs are elagolix, which is a gonadotropin-releasing hormone (GnRH) antagonist for endometriosis and uterine fibroids; INGREZZA (valbenazine), which is a vesicular monoamine transporter 2 (VMAT2) inhibitor, for the treatment of movement disorders, and opicapone, which is a selective catechol-O-methyltransferase inhibitor that is an adjunct therapy to preparations of levodopa/Dihydroxyphenylalanine (DOPA) decarboxylase inhibitors for adult patients with Parkinson’s disease.
Receive News & Ratings for Neurocrine Biosciences Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Neurocrine Biosciences Inc. and related companies with MarketBeat.com's FREE daily email newsletter.